RE:Failure rateI think PMN is will ultimately benefit from its scientifically rigorous approach as well as the wealth of data from alternative approaches that have missed the mark and support the PMN hypothesis.
PMN is threading the needle with their technology. Selectivity for the right target. It is crazy that they have known this for close to a decade, but it takes so long (and billions of dollars) for people to learn. Given what Accumen was claiming pre Phase 1, I think the landscape was very competitive and scared investors away. But now given that Acumen seems to have overstated their plaque avoidance, it seems PMN should have the momentum going forward. It will still take time, and many investors won't believe it til they see the trial data. After seeing what Acumen did with ARIA-E, I can't say I blame hesitant investors. Hopefully those of us who see it clearly today and trust the PMN research will be rewarded for our due diligence and not diluted too much.
The case is getting stronger for PMN. Hopefully that provides good leverage for Ph 2 financing at a reasonable price. If Acumen is a good guide, PMN is going to either need a $100M+ investment or partner with big pharma or get bought out.